AI-Based Precision Therapeutics
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
76
NCT05807971
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 6, 2023
Completion: Feb 8, 2024
Loading map...